PALI NASDAQ
Palisade Bio, Inc.
1W: -0.7%
1M: -27.6%
3M: -29.4%
YTD: -42.4%
1Y: +9.9%
3Y: -81.9%
5Y: -99.9%
$1.44
+0.01 (+0.70%)
Weekly Expected Move ±12.4%
$1
$1
$1
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (19)
Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts
Bank of New York Mellon Corp Takes $728,000 Position in Palisade Bio, Inc. $PALI
Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00
HC Wainwright Decreases Earnings Estimates for Palisade Bio
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Brookline Capital Markets Predicts Palisade Bio Q1 Earnings
Brokers Issue Forecasts for Palisade Bio Q3 Earnings
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
HC Wainwright Forecasts Palisade Bio Q1 Earnings
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference